Integer Holdings Revises 2026 Growth to -2%–2% After 40% YTD Stock Plunge
Integer Holdings reported 2026 organic growth now projected at -2% to 2% after three product orders fell short, triggering a stock drop of over 40% year-to-date. Shares closed at $85.23 with a 31.9% one-year decline and the company's market cap stands at $2.893 billion.
1. Q4 2025 Activist Letter
In its Q4 2025 letter, 13D Activist Fund highlighted Integer Holdings as a key pure-play medical device CDMO, noting its leadership in cardiovascular and neuromodulation applications due to high regulatory barriers and sticky OEM relationships.
2. Guidance Revision
The fund pointed out that market demand for three specific products fell short of OEM expectations, leading management to slash 2026 organic growth guidance to between -2% and 2%, down from a typical 6%–8% target.
3. Share Decline
Following the guidance cut, Integer’s stock plunged over 20% overnight and an additional 20% in subsequent sessions, leaving the share price down more than 40% year-to-date and 31.9% lower over the past 12 months.
4. Market Position and Outlook
Despite the downturn, Integer remains the only publicly traded pure-play CDMO in its niche with high barriers to entry; management insists the 2026 slowdown is temporary and expects growth to normalize in 2027, though transparency is limited by confidentiality constraints.